Northpointe Bancshares, Inc.

NYSE:NPB

Banks - Regional

Financial Services
$14.79 +0.11%

+$0.02 today

Market cap
$511.47M
Beta
0.11
P/E (TTM)
3.1
EPS (TTM)
$5.85
Dividend yield
0.56%
52W Low $12.95High $19.48

Volume 0.33M

Average 0.15M

NPB Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Northpointe Bancshares, Inc.NYSE: NPB

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables outflow grows to $0

Q1 FY2026 accounts payables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts payables was $0.

Context

  • Accounts payables amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Accounts payables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Accounts Payables vs competitors

How NPB compares with its peers on the latest reported figures

  • NPB's LTM Mar 2026 accounts payables of $0 is the smallest of the 7 companies compared; the peer median is $70.5K.
  • Accounts payables amounts to 0.0% of revenue for NPB, versus a peer median of 1.9%.
NPB Competitors Peer median
Accounts Payables for NPB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$26.31M -138.8%-15.0%1.9%
ZLABZai Lab LimitedLTM Jun 2026$16.33M +57.3%—3.6%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$892K +191.5%+18.1%—
ERASErasca, Inc.LTM Sep 2026$798K +27.9%-8.8%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026$233K -91.2%-54.6%—
CCCCC4 Therapeutics, Inc.LTM Mar 2026$92K +109.7%-48.0%0.3%
NPBNorthpointe Bancshares, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding NPB) $70.5K+42.6%-15.0%1.9%

Competitors are the stored peer set for NPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(361.52M)23.24M33.76M55.16M83.41M
Depreciation & Amortization4.89M0000
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital61.17M(9M)2.29M(21.82M)26.09M
Accounts Receivables10.21M0000
Inventory(4.22M)0000
Accounts Payables00000
Other Working Capital55.18M(9M)2.29M(21.82M)26.09M
Other Non-Cash Items144.57M(93.75M)(60.16M)(13.53M)(65.21M)
Operating Cash Flow(150.88M)(79.52M)(24.11M)19.81M44.29M
Capital Expenditures(4.64M)(3.39M)(2.81M)(1.05M)(2.77M)
Acquisitions (Net)00000
Purchases of Investments(1.58B)(5.82M)0(4M)0
Sales of Investments1.47B1.29M790K11.13M7.33M
Other Investing Activities0265.53M(217.66M)(464.31M)(1.63B)
Investing Cash Flow(112.76M)255.9M(222.41M)(458.24M)(1.63B)
Debt Repayment0(322M)332.75M(10.4M)235.49M
Common Stock Issued92.09M243K0155K116.62M
Common Stock Repurchased0(1.5M)(616K)(12.34M)(82.17M)
Dividends Paid0(17.41M)(12.22M)(11.58M)(11.43M)
Other Financing Activities0(14.09M)4.26M497M1.45B
Financing Cash Flow92.09M(354.76M)324.17M462.83M1.71B
Effect of Forex Changes(3.25M)178.37M(77.66M)(24.41M)(120.16M)
Net Change in Cash(174.79M)0000
Free Cash Flow(155.52M)(82.91M)(26.92M)18.76M41.53M

Northpointe Bancshares, Inc.

NYSE:NPB

Intrinsic Alpha fair value

Locked

Current Price

$14.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.